Back to Search
Start Over
Role of gut microbiota and metabolomics in the lipid-lowering efficacy of statins among Chinese patients with coronary heart disease and hypercholesterolemia.
- Source :
-
Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 Jul 25; Vol. 14, pp. 1408581. Date of Electronic Publication: 2024 Jul 25 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Background: Statins, being the primary pharmacological intervention for hypercholesterolemia, exhibit a notable degree of interpatient variability in their effectiveness, which may be associated with gut microbiota. This study sought to identify the biomarkers for evaluating differences in statin efficacy.<br />Methods: A quasi case-control study was conducted among participants with hypercholesterolemia and coronary heart disease taking rosuvastatin essential. According to the level of low density lipoprotein cholesterol (LDL-C), participants was divided into the "Up to standard" (US) group and the "Below standard" (BS) group. 16S rDNA sequencing and untargeted metabolomics were applied to detected the information of gut microbiota and related metabolites.<br />Results: A total of 8 US and 8 BS group matched by age and sex were included in the final analysis. 16S rDNA sequencing results indicated that the characteristic strains of the US group were f-Eubacterium&#95;coprostanoligenes and g-Papillibacter , while the characteristic flora of the BS group were o-C0119 , g-Pseudolabrys, s-Dyella-Marensis and f-Xanthobacaceae. Metabolomic results suggested that the levels of chenodeoxycholic acid-3-β-D-glucuronide, 1-methylnicotinamide and acetoacetate in stool samples of the US group were significantly higher than those of the BS group. By identifying the differentially abundant bacterial taxa, the gut microbiota could modulate the efficacy of statins through producing enzymes involved in cholesterol metabolism.<br />Conclusions: The findings suggest that the difference in statin efficacy may be related to gut microbiota strains that can produce short-chain fatty acids and secondary bile acids and affect the efficacy of statins by regulating the activities of cholesterol metabolite-related proteins. Metabolites related to short-chain fatty acids and secondary bile acids in the gut are expected to be biomarkers indicating the efficacy of statins.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Hu, Hu, zhang, Hu, Zhang, Zhang, Yu, Liu, Wang, Lin, Gong, Zhang, Li and Li.)
- Subjects :
- Aged
Female
Humans
Male
Middle Aged
Bacteria metabolism
Bile Acids and Salts metabolism
Biomarkers blood
Case-Control Studies
China
Cholesterol, LDL blood
Cholesterol, LDL metabolism
East Asian People
Feces microbiology
Metabolomics
RNA, Ribosomal, 16S genetics
Rosuvastatin Calcium therapeutic use
Treatment Outcome
Coronary Disease microbiology
Coronary Disease drug therapy
Coronary Disease metabolism
Gastrointestinal Microbiome
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Hypercholesterolemia drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2235-2988
- Volume :
- 14
- Database :
- MEDLINE
- Journal :
- Frontiers in cellular and infection microbiology
- Publication Type :
- Academic Journal
- Accession number :
- 39119290
- Full Text :
- https://doi.org/10.3389/fcimb.2024.1408581